AR and neoplasm: In addition, the recent Robinsonet al. paper highlighted that 71.3% of metastatic CRPC tumours carried AR pathway mutations, the majority in the AR itself but others in e.g. AR cofactors (NCoR1/2) and, again, the pioneer factor FOXA128.